Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling

Glioblastoma, a deadly brain tumor, shows limited response to standard therapies like temozolomide (TMZ). Recent findings from the REGOMA trial underscore a significant survival improvement offered by Regorafenib (REGO) in recurrent glioblastoma. Our study aimed to propose a 3D ex vivo drug response...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Mariangela Morelli, Francesca Lessi, Sara Franceschi, Gianmarco Ferri, Manuel Giacomarra, Michele Menicagli, Carlo Gambacciani, Francesco Pieri, Francesco Pasqualetti, Nicola Montemurro, Paolo Aretini, Orazio Santo Santonocito, Anna Luisa Di Stefano, Chiara Maria Mazzanti
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Subjects:	glioblastoma NADP(H) FLIM Regorafenib drug response organoids
Online Access:	https://www.mdpi.com/2073-4409/13/6/487